ecancer

Bortezomib based therapies for myeloma

Dr Paul Richardson - Hematologic Oncology Dept, Dana-Farber Cancer Institute

2 Jul 2009

AACR 2009: Common genetic variations and predisposition to cancer

Prof Bruce Ponder - Cancer Research UK, Cambridge Institute

14 May 2009

AACR 2009: 100 years of AACR

Dr Margaret Foti - CEO of the American Association for Cancer Research

14 May 2009

AACR 2009: Cancer stem cells and leukaemia

Prof Craig Jordan - James P Wilmot Cancer Center University of Rochester School of Medicine

14 May 2009

Myelodysplastic syndromes (MDS)

Prof Pierre Fenaux - Service d'Hématologie Clinique, Avicenne Hospital / Université Paris, France

6 May 2009

Innovation in the treatment of myelodysplastic syndromes

Prof Pierre Fenaux - Service d'Hématologie Clinique, Avicenne Hospital / Université Paris, France

6 May 2009

Epigenetics of myelodysplastic syndromes

Prof Pierre Fenaux - Service d'Hématologie Clinique, Avicenne Hospital / Université Paris, France

6 May 2009

Benefits of azacitidine for treatment of myelodysplastic syndromes

Prof Pierre Fenaux - Service d'Hématologie Clinique, Avicenne Hospital / Université Paris, France

6 May 2009

AACR 2009: Genetic susceptibility for chronic lymphocytic leukaemia

Professor Susan Slager - Division of Biostatistics, Mayo Clinic College of Medicine, USA

30 Apr 2009

AACR 2009: Membrane microfilter device for capture and characterisation of circulating tumour cells

Anthony Williams - Keck School of Medicine, University of Southern California

30 Apr 2009

AACR 2009: Frequent JAK Mutations in Pediatric Acute Lymphoblastic Leukemia (ALL) with Poor Outcome: A New Therapeutic Target in Resistant Disease

Dr Charles Mullighan - Department of Pathology, St Jude Children's Research Hospital

30 Apr 2009

Bacteria as agents to initiate potent anti-tumour activity

Dr Maria Rescigno - Deptartment of Experimental Oncology, European Institute of Oncology, Milan

31 Mar 2009

More from ecancer